Skip to main content
Top
Published in: Clinical Rheumatology 4/2014

01-04-2014 | Original Article

The degree of asymptomatic hyperuricemia and the risk of gout. A retrospective analysis of a large cohort

Authors: Hadar Duskin-Bitan, Eytan Cohen, Elad Goldberg, Tzippy Shochat, Amos Levi, Moshe Garty, Ilan Krause

Published in: Clinical Rheumatology | Issue 4/2014

Login to get access

Abstract

This study was conducted to examine the relationship between the degree of asymptomatic hyperuricemia and the development of gout, in men and women. The database of a screening center was searched for all subjects with asymptomatic hyperuricemia (>7.0 mg/dl men, >5.6 mg/dl women) during 2000–2012. We included men and women without previous diagnosis of gout, and a follow-up of at least 5 years. The risk of gout was analyzed in relation to the degree of hyperuricemia at the first visit. Of the 5,234 subjects who matched the inclusion criteria, 4,241 were normouricemic at their first visit and 993 were hyperuricemic. The mean follow up period was 7.5 years. Gout was diagnosed at the last visit in 34 subjects; four in the normouricemia group and 30 in the hyperuricemia group (0.1 % vs. 3.0 %, p < 0.001). Only one woman developed gout. The odds ratio (OR) for developing gout was 32 times higher in the hyperuricemic group than in the normouricemic group. The OR to develop gout was 11.2 (confidence interval [CI] 3.6–35.2) in men with mild hyperuricemia compared to 107.1 (CI 34.2–334.9) in men with moderate hyperuricemia, and 624.8 (CI 134.0–2,913.1) in men with severe hyperuricemia. Multivariate analysis of uric acid levels, thiazide use, regular alcohol consumption and estimated glomerular filtration rate (eGFR) showed that only the level of uric acid retained statistically significant for increasing the risk of gout. There is a strong association between the absolute level of uric acid and the risk to develop gout, strikingly so for men with severe hyperuricemia. Monitoring is recommended for that group, which poses the greatest risk to develop gout.
Literature
2.
go back to reference Campion EW, Glynn RJ, DeLabry LO (1987) Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 82:421–426PubMedCrossRef Campion EW, Glynn RJ, DeLabry LO (1987) Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 82:421–426PubMedCrossRef
3.
go back to reference Hall AP, Barry PE, Dawber TR, McNamara PM (1967) Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med 42:27–37PubMedCrossRef Hall AP, Barry PE, Dawber TR, McNamara PM (1967) Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med 42:27–37PubMedCrossRef
4.
go back to reference Roubenoff R (1990) Gout and hyperuricemia. Rheum Dis Clin North Am 6:539–550 Roubenoff R (1990) Gout and hyperuricemia. Rheum Dis Clin North Am 6:539–550
5.
go back to reference Trifirò G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M et al (2013) Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: a nationwide population-based study. Ann Rheum Dis 72:694–700PubMedCrossRef Trifirò G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M et al (2013) Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: a nationwide population-based study. Ann Rheum Dis 72:694–700PubMedCrossRef
6.
go back to reference Zhu Y, Pandya BJ, Choi HK (2012) Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med 125:679–687PubMedCrossRef Zhu Y, Pandya BJ, Choi HK (2012) Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med 125:679–687PubMedCrossRef
7.
go back to reference Arromdee E (2002) Epidemiology of gout: is the incidence rising? J Rheumatol 29:2403–2406PubMed Arromdee E (2002) Epidemiology of gout: is the incidence rising? J Rheumatol 29:2403–2406PubMed
9.
go back to reference Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T (2008) Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis 67:960–966PubMedCentralPubMedCrossRef Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T (2008) Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis 67:960–966PubMedCentralPubMedCrossRef
11.
go back to reference Mikuls T, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG (2005) Gout epidemiology: results from the UK General Practice Research Database, 1990–1999. Ann Rheum Dis 64:267–272PubMedCentralPubMedCrossRef Mikuls T, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr, Saag KG (2005) Gout epidemiology: results from the UK General Practice Research Database, 1990–1999. Ann Rheum Dis 64:267–272PubMedCentralPubMedCrossRef
12.
go back to reference Gutiérrez-Macías A, Lizarralde-Palacios E, Martínez-Odriozola P, Miguel-De la Villa F (2005) Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia. BMJ 331:623–624PubMedCentralPubMedCrossRef Gutiérrez-Macías A, Lizarralde-Palacios E, Martínez-Odriozola P, Miguel-De la Villa F (2005) Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia. BMJ 331:623–624PubMedCentralPubMedCrossRef
13.
go back to reference Hammer B, Link A, Wagner A, Böhm M (2001) Hypersensitivity syndrome during therapy with allopurinol in asymptomatic hyperuricemia with a fatal outcome. Dtsch Med Wochenschr 126:1331–1334PubMedCrossRef Hammer B, Link A, Wagner A, Böhm M (2001) Hypersensitivity syndrome during therapy with allopurinol in asymptomatic hyperuricemia with a fatal outcome. Dtsch Med Wochenschr 126:1331–1334PubMedCrossRef
14.
go back to reference Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T et al (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 64:1447–1461CrossRef Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T et al (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 64:1447–1461CrossRef
15.
go back to reference Kratz A, Pesce MA, Fink DJ (2012) Laboratory values of clinical importance. In: Fauci AS, Braunwald E, Kasper D et al (eds) Harrison principles of internal medicine, 18th edn. McGraw Hill, New York, USA, p 3596 Kratz A, Pesce MA, Fink DJ (2012) Laboratory values of clinical importance. In: Fauci AS, Braunwald E, Kasper D et al (eds) Harrison principles of internal medicine, 18th edn. McGraw Hill, New York, USA, p 3596
16.
go back to reference Min SI, Yun IJ, Kang JM, Park YJ, Min SK, Ahn C et al (2009) Moderate to severe early onset hyperuricemia: a prognostic marker of long term kidney transplant outcome. Nephrol Dial Transplant 24:2584–2590PubMedCrossRef Min SI, Yun IJ, Kang JM, Park YJ, Min SK, Ahn C et al (2009) Moderate to severe early onset hyperuricemia: a prognostic marker of long term kidney transplant outcome. Nephrol Dial Transplant 24:2584–2590PubMedCrossRef
17.
go back to reference Schumacher HR, Chen LX (2012) Gout and other crystal-associated arthropathies. In: Fauci AS, Braunwald E, Kasper D et al (eds) Harrison principles of internal medicine, 18th edn. McGraw Hill, New York, USA, pp 2012–2837 Schumacher HR, Chen LX (2012) Gout and other crystal-associated arthropathies. In: Fauci AS, Braunwald E, Kasper D et al (eds) Harrison principles of internal medicine, 18th edn. McGraw Hill, New York, USA, pp 2012–2837
18.
go back to reference Lally E, Ho G Jr, Kaplan SR (1986) The clinical spectrum of gouty arthritis in women. Arch Intern Med 146:2221–2225PubMedCrossRef Lally E, Ho G Jr, Kaplan SR (1986) The clinical spectrum of gouty arthritis in women. Arch Intern Med 146:2221–2225PubMedCrossRef
19.
go back to reference Puig J, Michán AD, Jiménez ML, Pérez de Ayala C, Mateos FA, Capitán CF et al (1991) Female gout. Clinical spectrum and uric acid metabolism. Arch Intern Med 151:726–732PubMedCrossRef Puig J, Michán AD, Jiménez ML, Pérez de Ayala C, Mateos FA, Capitán CF et al (1991) Female gout. Clinical spectrum and uric acid metabolism. Arch Intern Med 151:726–732PubMedCrossRef
20.
go back to reference Miao Z, Li C, Chen Y, Zhao S, Wang Y, Wang Z et al (2008) Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J Rheumatol 35:1859–1864PubMed Miao Z, Li C, Chen Y, Zhao S, Wang Y, Wang Z et al (2008) Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J Rheumatol 35:1859–1864PubMed
21.
go back to reference Langford HG, Blaufox MD, Borhani NO, Curb JD, Molteni A, Schneider KA et al (1987) Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med 47:645–649CrossRef Langford HG, Blaufox MD, Borhani NO, Curb JD, Molteni A, Schneider KA et al (1987) Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med 47:645–649CrossRef
22.
go back to reference Choi HK, Soriano LC, Zhang Y, Rodríguez LA (2012) Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 344:d8190:1–9 Choi HK, Soriano LC, Zhang Y, Rodríguez LA (2012) Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 344:d8190:1–9
23.
go back to reference Lin KC, Chou P (2000) The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 27:1501–1505PubMed Lin KC, Chou P (2000) The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 27:1501–1505PubMed
24.
go back to reference Cohen E, Krause I, Fraser A, Goldberg E, Garty M (2012) Hyperuricemia and metabolic syndrome: lessons from a large cohort from Israel. IMAJ 14:676–680PubMed Cohen E, Krause I, Fraser A, Goldberg E, Garty M (2012) Hyperuricemia and metabolic syndrome: lessons from a large cohort from Israel. IMAJ 14:676–680PubMed
25.
go back to reference Bilenko N, Fraser D, Vardi H, Shai I, Shahar DR (2005) Mediterranean diet and cardiovascular diseases in an Israeli population. Prev Med 40:299–305PubMedCrossRef Bilenko N, Fraser D, Vardi H, Shai I, Shahar DR (2005) Mediterranean diet and cardiovascular diseases in an Israeli population. Prev Med 40:299–305PubMedCrossRef
Metadata
Title
The degree of asymptomatic hyperuricemia and the risk of gout. A retrospective analysis of a large cohort
Authors
Hadar Duskin-Bitan
Eytan Cohen
Elad Goldberg
Tzippy Shochat
Amos Levi
Moshe Garty
Ilan Krause
Publication date
01-04-2014
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 4/2014
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-014-2520-7

Other articles of this Issue 4/2014

Clinical Rheumatology 4/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.